Tag: Protalix BioTherapeutics Inc. (PLX)

Protalix Bio Therapeutics, Inc. (PLX) stock soared 46.67% in the pre-market trading session at the price of $1.54 after reporting topline data from the BALANCE clinical trial evaluating PRX–102. PLX is a biopharmaceutical firm that develops and commercializes therapeutic proteins using its plant cell-based ProCellEx